ArticleInternal medicine (Tokyo, Japan)2017
Anti-mitochondrial M2 Antibodies Enhance the Risk of Supraventricular Arrhythmias in Patients with Elevated Hepatobiliary Enzyme Levels.
Article in Internal medicine (Tokyo, Japan), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Associations between anti-mitochondrial antibodies and cardiac involvement in idiopathic inflammatory myopathy patients : A systematic review and meta-analysis.Zeitschrift fur Rheumatologie · 2024Pooled it
- The Role of Antimitochondrial Antibodies in Atrial Cardiomyopathy: Causality or Coincidence?JACC. Case reports · 2026Article
- Pathological findings with vacuoles in anti-mitochondrial antibody-positive inflammatory myopathy.BMC musculoskeletal disorders · 2024Article
- Dilated cardiomyopathy with anti-mitochondrial M2 antibody: A case series.Journal of cardiology cases · 2023Article
- Sick sinus syndrome concomitant with myopathy associated with anti-mitochondrial antibodies: a case report.European heart journal. Case reports · 2023Article
- Nine-Second Cardiac Arrest in a Patient With Anti-mitochondrial Antibody-Positive Myopathy Under General Anesthesia.Cureus · 2023Article
- Life-threatening ventricular arrhythmia and left ventricular dysfunction associated with anti-mitochondrial antibody-positive myositis: a case report.European heart journal. Case reports · 2021Article
- Myositis with Anti-mitochondrial Antibody Type 2 with Diplopia and Ptosis.Internal medicine (Tokyo, Japan) · 2021Article
- Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy.Internal medicine (Tokyo, Japan) · 2021Article
- Management of tachyarrhythmias in pregnancy - A review.Obstetric medicine · 2020Review
- Acute Adrenal Insufficiency Precipitated by the Discontinuation of a Betamethasone and Dextrochlorpheniramine Combination: The Diagnostic Utility of an Echocardiographic Assessment of Systemic Vascular Resistance.Internal medicine (Tokyo, Japan) · 2019Article
- Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders.Internal medicine (Tokyo, Japan) · 2019Review
- Anti-mitochondrial M2 Antibodies and Myopathy: Author's Reply.Internal medicine (Tokyo, Japan) · 2018Article
- Anti-mitochondrial M2 Antibodies and Myopathy.Internal medicine (Tokyo, Japan) · 2018Article
- Bench to bedside review of myositis autoantibodies.Clinical and molecular allergy : CMA · 2018Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Supraventricular arrhythmias are commonly detected in patients with anti-mitochondrial antibody M2 (AMA-M2)-associated myopathy. However, the prevalence of supraventricular arrhythmias in unselected AMA-M2-positive patients and the impact of AMA-M2 on supraventricular arrhythmias have yet to be fully investigated. Methods We analyzed 384 patients (116 men; age, 60 [48-69] years), who underwent AMA-M2 testing following the detection of elevated hepatobiliary enzymes. Supraventricular arrhythmias involving atrial fibrillation, atrial flutter, atrial tachycardia, sick sinus syndrome, and atrial standstill were confirmed by a 12-lead electrocardiogram, 24-hour ambulatory monitoring, and physician-assigned diagnoses within the three years before and two years after the AMA-M2 test. Results Seventy-seven (20%) patients were positive for AMA-M2. The prevalence of supraventricular arrhythmias among AMA-M2-positive patients was higher than that among AMA-M2-negative patients (14% vs. 6%, p=0.008). A univariate analysis showed that supraventricular arrhythmias were associated with AMA-M2 positivity, aging, congestive heart failure, and the CHADS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.